Q-omics provides the consensus-scored CCDC103 profile across patient tissues and cancer cell-line models. CCDC103 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, CCDC103 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, CCDC103 RNA expression shows 11,292 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LGG, HNSC, and ACC as cancer lineages where CCDC103 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC103 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC103 survival associations across molecular data types. CCDC103 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC103 RNA expression–survival associations across cancer types. High CCDC103 expression shows unfavorable associations in LGG, CHOL, TGCT, COAD and KICH, but favorable associations in KIRC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for CCDC103 RNA expression.
This table summarizes CCDC103 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC103. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC103 shows lower tumor expression in KICH and LUSC and higher tumor expression in HNSC, LUAD, KIRP and KIRC. The HNSC box plot shows higher CCDC103 RNA expression in tumor versus normal tissue (log2 FC = +0.015, t-test p = .008).
This table shows molecular features associated with CCDC103 in patient tissues and cancer cell lines. In patient samples, CCDC103 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC103 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
